3 Stocks That Cut You a Check Each Month
Agree Realty is a small net lease REIT that is growing relatively quickly, including on the dividend front.
EPR Properties is a net lease REIT that is executing a business turnaround.
10 stocks we like better than Realty Income ›
Retired investors who have shifted from building a nest egg to living off their accumulated savings often start to focus on dividend stocks. Going with monthly pay dividend stocks is almost like creating your own paycheck.
That's why such investors will be interested in reliable dividend stalwart Realty Income (NYSE: O), growth-focused Agree Realty (NYSE: ADC), and turnaround story EPR Properties (NYSE: EPR).
With yields as high as 6.2%, here's a quick look at each one of these monthly dividend payers.
The similarity between Realty Income, Agree Realty, and EPR Properties is that all three are net lease real estate investment trusts (REITs). A net lease requires the tenant (there is usually just one for each property) to pay for most property-level operating costs. While any one property is high-risk, given that there's only one tenant, across a large portfolio, net leases materially reduce risk for the landlord.
Since the tenant has effective control of the property, which is the point of the lease structure, the property owner avoids a lot of costs that rise over time. All the hassle of maintaining the property goes onto the shoulders of the tenant. It's an attractive business model for a REIT. But REITs go about using the approach in different ways.
Realty Income is focused on scale and diversification. It's the largest net lease REIT you can buy, with more than 15,600 properties. The vast majority of its properties reside in the retail sector (about 75% of rents), but it also has material exposure to industrial assets and a diverse "other" category. The "other" grouping is somewhat opportunistic, including things like vineyards and casinos.
On top of this diversification, Realty Income also spreads its portfolio across both the North American and European markets. Overall, it's one of the most diversified REITs you can buy.
That said, Realty Income is a slow and steady tortoise. Given its size, it takes a lot to move the needle on the top and bottom lines. But the company has long prioritized returning value to shareholders via regular dividend increases. The monthly pay dividend has been increased annually for three decades, even though the roughly 4% annualized increase rate over that span isn't huge. With a dividend yield of 5.6%, however, if you are looking for a reliable dividend foundation for your portfolio, you'll probably find Realty Income to your liking.
Agree Realty competes directly with Realty Income. However, Agree is 100% retail focused and 100% U.S. focused. That said, the most important difference is probably the fact that Agree only owns around 2,400 properties. It is a much smaller business. While that's still a large portfolio, it means that smaller investments can still have a meaningful effect on Agree's growth. That, in turn, shows up in dividend growth.
Agree's dividend has been increased at roughly 6% a year over the past decade. That's just a couple of percentage points faster than Realty Income, but small amounts add up over time. Over the past 10 years, Agree's dividend has grown by a bit over 60%, while Realty Income's dividend has increased by about 40%. If you prefer dividend growth over yield, Agree Realty will probably be to your liking. But you'll have to give up yield to own it, since Agree's dividend yield is 4.1%.
EPR Properties has the highest yield here at 6.2%. It also has the worst dividend track record, with the dividend getting cut and briefly suspended during the early days of the coronavirus pandemic.
However, that makes a lot of sense when you consider the REIT's focus on experiential properties. When the government shut down non-essential businesses, properties like amusement parks, movie theaters, and ski resorts felt the sting. EPR Properties made the right call to ensure it had the liquidity to survive and to help its tenants survive.
The dividend is back in growth mode, though still below the pre-cut level. EPR Properties isn't quite out of the woods just yet on the business front, either. That's because it has material exposure to the movie theater space, which has been struggling as new forms of video entertainment (streaming, for example) gain share with consumers.
But management isn't ignoring the issue and has been working to focus on its best assets while, at the same time, working to improve its tenant roster. The business is a work in progress, but progress is being made. The added risk, if you appreciate turnaround stories, is made up for with the lofty yield.
Monthly pay dividend stocks are actually a pretty rare breed on Wall Street. However, high-yield REITs Realty Income, Agree Realty, and EPR Properties still offer a very diverse range of investment choices. Conservative investors will appreciate Realty Income, dividend growth investors will probably gravitate toward Agree, and more aggressive investors willing to deal with special situations stocks will want to dig into EPR's business rebound.
Before you buy stock in Realty Income, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!*
Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Reuben Gregg Brewer has positions in Realty Income. The Motley Fool has positions in and recommends EPR Properties and Realty Income. The Motley Fool has a disclosure policy.
3 Stocks That Cut You a Check Each Month was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Lucid Soars on Multimillion Uber Deal -- Can It Go Higher Still?
Key Points Lucid claims to have the world's most advanced electric vehicles. Uber will invest $300 million into Lucid. Lucid will use tech provided by Nuro to outfit its vehicles for driverless Uber operations. 10 stocks we like better than Lucid Group › Famous investor Benjamin Graham said: "In the short run, the market is a voting machine, but in the long run, it is a weighing machine." That quote sure holds true today, after Uber Technologies (NYSE: UBER) shook up the market with its announcement that it will deploy a fleet of robotaxis as demand for autonomous driving vehicles begins to fire on all cylinders. If the market is indeed a short-term voting machine, the market has cast its vote, and Lucid Motors (NASDAQ: LCID) looks like the real winner of this partnership. Lucid's stock popped well over 40% on the news, while Uber traded marginally higher. Let's dig into what this massive development means for the young electric vehicle (EV) maker. Best of the best? When it comes to selecting partners for such a massive deal, Uber could have done a lot worse than selecting the EV company that's brash enough to claim "maker of the world's most advanced electric vehicles." More specifically, on Thursday, Uber announced a partnership that would unleash more than 20,000 robotaxis over the next six years. As previously mentioned, part of the partnership includes Lucid, but another partner is also in the mix: Nuro, an autonomous vehicle start-up. It breaks down like this: Uber will invest $300 million in Lucid, while Nuro develops the self-driving technology that Lucid will deploy in its vehicles to supply Uber with robotaxis. "This investment from Uber further validates Lucid's fully redundant zonal architecture and highly capable platform as ideal for autonomous vehicles, and our industry-leading range and spacious well-appointed interiors, as ideal for ridesharing," said Marc Winterhoff, Interim CEO at Lucid, in a press release. "This is the start of our path to extend our innovation and technology leadership into this multi-trillion-dollar market." This development is a pretty big deal for Lucid. While manufacturing of the 20,000 vehicles in question will be spread over six years and unlikely to start until late next year, it still represents a strong order for the company that just set a quarterly record for deliveries at only 3,309 vehicles, during the second quarter. Moreover, consider that Lucid delivered only 6,418 vehicles during the first half of 2025, and you can understand that 20,000 vehicles for Uber is nothing to sneeze at. In fact, it's about as many vehicles as Lucid hopes to deliver for the full year. Strategic change This partnership marks a new era for Uber, which previously exited the robotaxi space in 2020, and signals that the company's strategy going forward will revolve around partnerships with multiple technology developers. It's also not the only deal Uber is working on. In April, the company announced that Volkswagen will supply its vans for commercial service in Los Angeles next year. While Uber is the driving force behind this multi-million-dollar partnership, it arguably has the roughest road ahead. Driverless vehicle technology has been more challenging and more costly than anticipated, and it's dealing with tight regulations and federal investigations. Those hurdles caused many start-ups to close their doors, including General Motors' Cruise and Ford Motor Company's Argo AI. Uber also has some catching up to do in terms of driverless capabilities. Despite years of delays and missed targets, Tesla did start a pilot program with about a dozen Model Y EVs in Austin, Texas, in June, with plans to expand the service to other U.S. cities later this year. Waymo has also been methodically and quietly growing its operations for years in several U.S. cities with a fleet of roughly 1,500 vehicles. It just crossed 100 million miles of autonomous driving in July. Ultimately, this opens the door to new opportunities for all three companies. But if the market is indeed a voting machine in the short term, there is reason for Lucid investors to be excited. This gets the company's product in front of new customers, in a new addressable market, with partnerships that were once untapped -- it's a big deal, even aside from the $300 million investment. Lucid has a lot of momentum behind it right now, and if the Gravity SUV continues to accelerate its production and deliveries flawlessly, the young EV maker should enter 2026 poised for a tremendous year. While Lucid is likely to give back some of Thursday's large gains, there's little stopping Lucid's stock from climbing higher as deliveries ramp for the Gravity -- especially if the automaker can curb costs and cash burn in the year ahead. Should you buy stock in Lucid Group right now? Before you buy stock in Lucid Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Daniel Miller has positions in Ford Motor Company and General Motors. The Motley Fool has positions in and recommends Tesla and Uber Technologies. The Motley Fool recommends General Motors and Volkswagen Ag. The Motley Fool has a disclosure policy. Lucid Soars on Multimillion Uber Deal -- Can It Go Higher Still? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
5 High-Yield Stock Picks to Add to Your Dividend Portfolio
Key Points Verizon and Realty Income may not offer much growth, but their ability to fund growing dividend payments is rock-solid. Pfizer struggled following the wind-down of the coronavirus pandemic, with nothing offsetting declining sales of Paxlovid. That's changing. Exchange-traded funds are an easy diversification solution for at least a portion of your dividend portfolio. 10 stocks we like better than Pfizer › Does the prospect of economic uncertainty have you rethinking your portfolio? Perhaps you'd like to collect a little more cash while the economic headwinds are blowing? It's not an unreasonable concern. Plenty of other investors are already thinking more defensively than they've felt they needed to in a while. To this end, here's a closer look at five high-yielding dividend stocks to consider adding to your portfolio sooner rather than later, until it's clear the worst is behind us. 1. Verizon Communications Dividend yield: 6.2% Verizon Communications (NYSE: VZ) is, of course, one of the country's biggest wireless service providers, boasting well over 100 million paying customers who collectively handed over nearly $135 billion worth of revenue last year alone. Of that, $18 billion was turned into net income, $11.25 billion of which was dished out to shareholders in the form of dividends. That's in line with the company's long-term norms. There is an arguable downside here. That's growth ... or lack thereof. The well-saturated U.S. wireless market doesn't offer much in the way of upside potential above and beyond simple population growth. Verizon is finding some inroads within the institutional/private 5G communications space, but that's a highly competitive market. There's just not a ton of expansion to be added here either. What Verizon may lack in growth potential, however, it more than makes up for in consistency and sheer payout. Nobody's interested in giving up their mobile phones, which supports a sizable forward-looking yield of 6.2% that's based on a dividend that has now been raised for 18 consecutive years. Not bad. 2. Realty Income Dividend yield: 5.6% Realty Income (NYSE: O) isn't a stock in the traditional sense. Rather, it's a real estate investment trust, or REIT. That just means it owns a portfolio of rent-bearing real estate. REITs trade just like ordinary stocks do, and pay dividends the same way that dividend stocks do, too. And Realty Income brings something else to the table that's pretty unique in addition to its sizable forward-looking yield of 5.6%. That's a monthly dividend payment, as opposed to the quarterly cadence you'll get with most other dividend stocks. Realty Income's specialty is retailing real estate. In light of the so-called "retail apocalypse" that seems to never end, this focus seems like a liability. Just take a step back and look at the bigger picture. While numbers from Coresight Research point out that 7,325 U.S. stores were shuttered last year, 5,970 new stores were opened (or reopened). Realty Income further narrows this gap by serving the strongest survivors in the business. Its top tenants include 7-Eleven, Dollar General, Dollar Tree, and FedEx, just to name a few. Underscoring the quality caliber of its renters is the fact that its occupancy rate currently stands at an industry-beating 98.5%, and only fell to 97.9% in COVID-crimped 2020. This resilience is one of the reasons the REIT has been able to raise its payout annually for the past 30 consecutive years. 3. SPDR Portfolio S&P 500 High Dividend ETF Dividend yield: 4.6% Speaking of dividend stocks that aren't actually stocks, add the SPDR Portfolio S&P 500 High Dividend ETF (NYSEMKT: SPYD) to your watch list, if not to your portfolio. An ETF (or exchange-traded fund) is a basket of stocks with a common characteristic. In this instance, these tickers are all part of the S&P 500 High Dividend Index, which tracks the 80 highest-yielding names within the S&P 500. These include Philip Morris, toymaker Hasbro, AT&T, and Ford Motor Company, for reference. None of these names has a great deal of growth firepower. All of them, however, are healthy dividend payers. Most of them also have a solid track record of dividend growth, even if it's not required for inclusion in the underlying index. Sure, you can probably find higher dividend yields than the one SPYD offers. The aforementioned Realty Income and Verizon both boast bigger ones, for instance. The SPDR Portfolio S&P 500 High Dividend ETF is still an incredibly simple way of achieving a well-diversified mix of dividend stocks though, with a little more potential for capital appreciation than Verizon or Realty Income offer. 4. Pfizer Dividend yield: 6.9% It's no secret that drugmaker Pfizer (NYSE: PFE) has underperformed since the wind-down of COVID-19, which upended sales of its Paxlovid approved to treat the disease. The company's top line has slipped from 2022's $100 billion to only $64 billion last year, for perspective, and analysts aren't looking for any sales growth this year or next either. That's the chief reason Pfizer shares continue to flounder. If you can look just a little further down the road though, some new blockbuster drugs are in the works -- drugs like vepdegestrant, for the treatment of ER+/HER2- metastatic breast cancer. While it will be competing with plenty of other therapies in this same space, it's noteworthy that the FDA fast-tracked this drug, which is being co-developed with Arvinas. And that's just one. Pfizer got a total of four promising oncology drugs with its 2023 acquisition of Seagen, and now has over 100 clinical trials underway, 30 of which are in phase 3 (late-stage) testing. Indeed, the company believes it's got eight oncology candidates in its developmental pipeline that could become blockbusters by 2030. Little of this long-term upside is being reflected in the stock's present price, however, even though it arguably should be. More to the point for interested income investors, this pharmaceutical stock's weakness has pushed its forward-looking dividend yield up to nearly 7% at a point where the pharma giant is on the verge of significant prolonged revenue and profit growth. 5. Global X Nasdaq 100 Covered Call ETF Dividend yield: 14% Finally, consider adding a stake in the Global X Nasdaq 100 Covered Call ETF (NASDAQ: QYLD) to your dividend portfolio. It's not a stock. It's an exchange-traded fund. And an unusual one at that. While it holds the same tickers that make up the tech-heavy Nasdaq-100 index, serving as an index fund isn't its primary purpose. Rather, this ETF's purpose is to generate reliable income that's regularly distributed to shareholders by selling covered calls against the ETF's stock holdings. It's an income-generating process called "buy-write," in fact -- you're buying a stock, and then "writing" (or selling) call options on those shares, essentially using them as collateral. And the process works. Although the income generated by writing covered calls over and over again can be erratic (don't count on that trailing 14% yield going forward), the resulting reliable yields are typically big even if they're not precisely predictable. There's also a big downside, though. That is, this fund is almost certainly guaranteed to underperform the Nasdaq-100 itself, even after factoring in all of its sizable dividend payments. That's just the nature of selling covered calls -- the strategy doesn't let you fully participate when the market's rallying the most. Writing options is just a means of monetizing stock holdings when they're mostly moving sideways, or losing ground. Still, with a double-digit yield, even only capturing a portion of the Nasdaq-100's long-term upside isn't a bad bet. It's just arguably not the only dividend-paying investment you'd want to own at any given time, mostly due to its inconsistent payments. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 James Brumley has positions in AT&T. The Motley Fool has positions in and recommends FedEx, Pfizer, and Realty Income. The Motley Fool recommends Hasbro, Philip Morris International, and Verizon Communications. The Motley Fool has a disclosure policy. 5 High-Yield Stock Picks to Add to Your Dividend Portfolio was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
